ArticleBMC urology2025

A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia.

Chi-Hang Yee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.